Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis

1 Aug 2023

Abstract excerpt

Immune checkpoint blockade (ICB) therapies display clinical efficacy in microsatellite instable (MSI) endometrial cancer (EC) treatment, the key mechanism of which is reversing T cell exhaustion and restoration of anti-tumor immunity. Here, we demonstrate that transcription factor 19 (TCF19), one of the most significantly differentially expressed genes between MSI and microsatellite stable (MSS) patients in The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37566545
DOI: 10.1016/j.celrep.2023.112944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axisPMID 37566545Read ↗

Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.Semantic proximity Read ↗

The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025.Semantic proximity Read ↗

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune MicroenvironmentSemantic proximity Read ↗

LATS1/2 Loss Promote Tumor Immune Evasion in Endometrial Cancer through Downregulating MHC-I ExpressionSemantic proximity Read ↗

CXCL9 and CXCL13 coordinately shape the immune-activated microenvironment of endometrial cancer via tertiary lymphoid structure formationSemantic proximity Read ↗

N-Myc and STAT Interactor is an endometriosis suppressorSemantic proximity Read ↗

Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancerSemantic proximity Read ↗

Keratin 17 Drives Endometrial Cancer Aggressiveness via Epithelial-Mesenchymal Transition: A Single-Cell Transcriptomic and Integrative Bioinformatics StudySemantic proximity Read ↗

TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosisSemantic proximity Read ↗

Ubiquitin Ligase TRIM22 Inhibits Ovarian Cancer Malignancy via TCF4 DegradationSemantic proximity Read ↗

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer.Semantic proximity Read ↗

TRIM21 deficiency promotes cell proliferation and tumorigenesis via regulating p21 expression in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.